Ligand Pharmaceuticals IncNASDAQ:LGND
- LAST PRICE69.7000
- TODAY'S CHANGE (%)1.5400 (2.2594%)
- Bid / Lots60.0000/ 1
- Ask / Lots86.7700/ 2
- Open / Previous Close68.4700 / 68.1600
- Day Range
- 52 Week Range
- Volume67,557
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LGND |
|---|---|---|
| 09:32 ET | 242 | 68.47 |
| 09:37 ET | 100 | 68.35 |
| 09:51 ET | 100 | 69.23 |
| 10:04 ET | 145 | 69.44 |
| 10:09 ET | 200 | 69.15 |
| 10:22 ET | 203 | 69.3774 |
| 10:24 ET | 294 | 69.5 |
| 10:26 ET | 200 | 69.19 |
| 10:29 ET | 100 | 69 |
| 10:40 ET | 192 | 69 |
| 10:42 ET | 105 | 68.69 |
| 10:49 ET | 200 | 69.19 |
| 11:20 ET | 200 | 69.27 |
| 11:43 ET | 300 | 69.76 |
| 11:59 ET | 800 | 69.5 |
| 12:01 ET | 100 | 69.435 |
| 12:10 ET | 100 | 69.57 |
| 12:14 ET | 1400 | 69.22 |
| 12:37 ET | 100 | 69.5899 |
| 12:51 ET | 200 | 69.58 |
| 01:02 ET | 630 | 69.355 |
| 01:04 ET | 100 | 69.35 |
| 01:06 ET | 100 | 69.365 |
| 01:18 ET | 100 | 69.32 |
| 01:27 ET | 100 | 69.39 |
| 01:38 ET | 100 | 69.35 |
| 01:44 ET | 200 | 69.42 |
| 01:45 ET | 185 | 69.39 |
| 01:49 ET | 100 | 69.54 |
| 02:02 ET | 500 | 69.45 |
| 02:12 ET | 100 | 69.49 |
| 02:16 ET | 980 | 69.67 |
| 02:43 ET | 1000 | 69.72 |
| 02:50 ET | 100 | 69.614 |
| 03:12 ET | 400 | 69.56 |
| 03:19 ET | 600 | 69.56 |
| 03:21 ET | 100 | 69.57 |
| 03:30 ET | 100 | 69.64 |
| 03:32 ET | 100 | 69.65 |
| 03:33 ET | 100 | 69.6505 |
| 03:46 ET | 100 | 69.78 |
| 03:48 ET | 700 | 69.51 |
| 03:50 ET | 200 | 69.27 |
| 03:51 ET | 1093 | 69.675 |
| 03:53 ET | 400 | 69.565 |
| 03:55 ET | 500 | 69.68 |
| 03:57 ET | 300 | 69.79 |
| 04:00 ET | 2084 | 69.7 |
Jan 6, 2023
Novan Submits New Drug Application to US FDA for Berdazimer Gel; Shares Down, from 10:27AM ET on Friday Jan 06, 2023 by MT Newswires
10:27AM ET on Friday Jan 06, 2023 by MT NewswiresBRIEF-Novan Submits NDA To U.S. FDA For Berdazimer Gel, 10.3%, from 8:23AM ET on Friday Jan 06, 2023 by Thomson Reuters
8:23AM ET on Friday Jan 06, 2023 by Thomson ReutersLigand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum, from 8:05AM ET on Friday Jan 06, 2023 by Business Wire
8:05AM ET on Friday Jan 06, 2023 by Business Wire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ligand Pharmaceuticals Inc | 1.2B | -55.0x | --- |
Travere Therapeutics Inc | 1.4B | -5.4x | --- |
CareDx Inc | 784.3M | -10.7x | --- |
Agenus Inc | 722.1M | -3.3x | --- |
Vericel Corp | 1.3B | -71.6x | --- |
Adaptive Biotechnologies Corp | 1.3B | -5.9x | --- |
Company Information
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.
Contact Information
- Headquarters
- 3911 Sorrento Valley Blvd, Suite 110SAN DIEGO, CA, United States 92121
- Phone
- 858-550-7500
- Fax
- 302-636-5454
Executives
- Non-Executive Independent Chairman of the Board
- John Kozarich
- President, Chief Operating Officer
- Matthew Korenberg
- Chief Executive Officer, Director
- Todd Davis
- Chief Financial Officer
- Octavio Espinoza
- Independent Director
- Jason Aryeh
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
|---|---|
Revenue (TTM) | $241.7M |
Shares Outstanding | 16.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.10 |
EPS | $-1.27 |
Book Value | $48.97 |
P/E Ratio | -55.0x |
Price/Sales (TTM) | 4.8 |
Price/Cash Flow (TTM) | 35.7x |
Operating Margin | 3.23% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
